A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Eligibility Criteria

• * Ability to understand and willingness to sign a written informed consent document.
• * Age ≥18 years.
• * Newly diagnosed have histologically or cytologically proven adenocarcinoma of the pancreas.
• * Tumor must be resectable.
• * Patient's acceptance to have a tumor biopsy.
• * ECOG performance status 0 or 1
• * Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
• * For both Women and Men, must use acceptable form of birth control while on study.
• * Have received any anti-pancreatic cancer therapy.
• * Have been diagnosed with another malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study.
• * Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures
• * Subjects with active, known or suspected autoimmune disease that may relapse.
• * Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.
• * Active infection requiring systemic therapy.
• * Infection with HIV or hepatitis B or C at screening•
• * History of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.
• * Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, pulmonary embolism, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
• * Prior allogeneic stem cell transplantation or organ transplantation
• * Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.
• * Have received a live vaccine ≤ 28 days before first dose of study drug.
• * Use of QT prolonging drugs within 2 weeks before the start of SX-682 dosing and for the length of the study.
• * ECG demonstrating a QTc interval ≥ 470 msec or patients with congenital long QT syndrome.
• * Severe hypersensitivity reaction to any monoclonal antibody.
• * Concurrent participation in another therapeutic clinical study
• * Pregnant or breastfeeding